Top 2014 IPOs for Orphan Drug Developers So Far

In Partnering & Investment by Cameron

This list takes a look at the top orphan drug developers whose initial public offerings (IPOs) have earned them a place amongst the 25 highest grossing biotech IPOs so far this year.


#7 – MediWound

Overall Rank: #16
 Approximately $80 million
Date: March 20
Shares/Price: 5.75 million shares at $14
Listing/Market: MDWD – NASDAQ Global Market

Orphan Product: NexoBrid
Indication: removal of eschar (debridement) in adults with deep partial- and full-thickness thermal burns
Stage: Starting phase III in the US


#6 – Auspex

 $87.1 million in net proceeds
Date: February 5th
Shares/Price: 8.05 million shares at $12
Listing/Market: ASPX – NASDAQ Global Market

Key Product: SD-809
Indication: Chorea (abnormal involuntary movements) associated with Huntington’s disease
 Phase III ongoing

Orphan Pipeline: Hemophilia B, Sanfilippo, Acute Intermittent Porphyria (AIP)


#5 UniQure

 $85.4 million after commissions but before expenses
Date: February 5th
Shares/Price: 5.4 million shares at $17
Listing/Market: QURE – NASDAQ Global Select Market

Key Product: Glybera
Indication: Gene therapy for Lipoprotein Lipase Deficiency LPLD
Stage: Marketing approval from the EMA


#4 – Zafgen

 $110.4 million in gross proceeds
Date: June 19
Shares/Price: 6.9 million shares at $16
Listing/Market: ZFGN – NASDAQ Global Market

Orphan Product: Beloranib (Fumagillin-calss MetAP2i)
Indication: Prader-Willi Syndrome
Stage: Orphan drug designation granted rom the EMA; Initiate phase 2b/3 trial in the second half of 2014
Info: Beloranib unexpectedly showed promise as an obesity drug. This promise is likely the cause behind the surge Zafgen experienced in the early days of their IPO.


Next Page >